Back to Search
Start Over
Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
- Source :
- Journal of Clinical Medicine, Journal of Clinical Medicine, Vol 9, Iss 3889, p 3889 (2020)
- Publication Year :
- 2020
- Publisher :
- MDPI, 2020.
-
Abstract
- Colorectal cancer (CRC) is a commonly diagnosed malignancy. The prognosis of patients with unresectable, metastatic colorectal cancer (mCRC) is dismal and medical treatment is mainly palliative in nature. Although chemotherapy remains the backbone of treatment, the landscape is changing with the understanding of its heterogeneity and molecular biology. First-line therapy relies on a combination of chemotherapy and targeted therapies, according to clinical patient characteristics and tumor molecular profile. Here we review current evidence from randomized clinical trials for using chemotherapy doublets or triplets, and for the addition of bevacizumab or anti-epidermal growth factor receptor (EGFR) agents. Novel therapies developed for small, selected populations are also discussed.
- Subjects :
- Oncology
medicine.medical_specialty
targeted agents
Bevacizumab
Colorectal cancer
medicine.medical_treatment
lcsh:Medicine
Unresectable disease
colorectal cancer
Review
Malignancy
chemotherapy
law.invention
03 medical and health sciences
0302 clinical medicine
First line therapy
Growth factor receptor
Randomized controlled trial
law
Internal medicine
medicine
030212 general & internal medicine
Chemotherapy
business.industry
lcsh:R
General Medicine
medicine.disease
030220 oncology & carcinogenesis
business
metastatic disease
medicine.drug
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Journal of Clinical Medicine, Journal of Clinical Medicine, Vol 9, Iss 3889, p 3889 (2020)
- Accession number :
- edsair.doi.dedup.....0e53b1e9f59754c7960641e4b79028ad